Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Immune checkpoint blockade has reached the standard of care for patients with lung cancer. However, its mode of action in patients is still incompletely understood. In this issue, Pai et al. present a temporally and spatially resolved differentiation map of tumor-directed T cells in patients with lung cancer on PD-1 blockade.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccell.2023.02.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Not all type of lepidic pattern is useful for distinguishing whether metachronous multiple lung adenocarcinomas are separate primary lung cancers.
Pathol Res Pract
September 2025
Department of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China. Electronic address:
Our research aims to ascertain the value of precursor and outgrowth lepidic in aiding the confirmation of multiple lung adenocarcinomas as separate primary lung cancers (SPLC). A total of 151 patients with metachronous multiple invasive adenocarcinomas were included in this study. Driver mutation tests（at least five genes: EGFR, ALK, KRAS, BRAF, and ROS1） were conducted on 302 tumors collected from 151 patients.
View Article and Find Full Text PDFHealth Inequity in People with Cystic Fibrosis: Can We Close the Gap?
Ann Am Thorac Soc
September 2025
Hadassah Medical Center, Pediatric Pulmonology Unit and Cystic Fibrosis Center, Jerusalem, Jerusalem, Israel.
Background Although advances in care have improved cystic fibrosis (CF) outcomes in higher-income countries (HICs), the situation remains alarming in lower-income countries (LICs). Methods People with CF (pwCF) enrolled in the European Cystic Fibrosis Society Patient Registry (ECFSPR) and carrying at least one F508del variant allele were evaluated in 2017 and in 2022 for predicted percent forced expiratory volume (ppFEV1), underweight status, and chronic Pseudomonas aeruginosa (Pa) infection, according to the gross national income (GNI) per capita divided into three terciles (low-income countries, LICs; middle-income countries, MICs; and high-income countries, HICs). Survival was evaluated in the periods 2013-2017 and 2018-2022.
View Article and Find Full Text PDFComments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.
JCO Precis Oncol
September 2025
Shu-Ning Li, MS, Jun-Nv Xu, MD, PhD,and Nan-Nan Ji, MD, PhD, Department of Radiation Oncology, Cancer Treatment Center, The Second Affiliated Hospital of Hainan Medical University, Haikou, China, Ming Xue, MS, Department of Outpatient, The Second Affiliated Hospital of Hainan Medical University, Hai
Identification of Targetable Mutations in Ovarian Cancer.
JCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFReply to: Comments on the Study of Outcomes After Radiation for Oligoprogressive Disease Sites in Patients With -Mutant Lung Cancer.
JCO Precis Oncol
September 2025
Monica F. Chen, MD, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Daniel Gomez, MD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, and Helena A. Yu, MD, Division of Solid Tumor Oncology, Depart